In quantitative research, the base rates are brutal. Test enough candidate strategies against enough historical data and impressive results will appear by chance alone; multiple-testing arithmetic guarantees it. Practitioner experience and the academic replication record converge on the same conclusion: the overwhelming majority of promising trading ideas are false discoveries. Accepting this is not pessimism. It is the foundation of rational research economics, and it implies that the central task of a research organization is efficient, honest killing.
The Asymmetry of Error
The two errors of strategy research carry wildly different price tags. A true negative, an idea correctly killed, costs computation and a brief span of attention. A false positive that reaches deployment costs real capital, months of misallocated monitoring, risk budget that stronger strategies could have used, and the institutional erosion that follows every unexplained loss. One deployed false positive can outweigh a hundred efficient rejections, which is why our pipeline is engineered to reject by default.
Engineering Cheap Deaths
Fast falsification must be designed, not hoped for. We sequence the validation gauntlet so the cheapest and most lethal tests run first: transaction-cost stress tests and causal backtests with no look-ahead eliminate most candidates before the costlier out-of-sample and walk-forward stages begin. Our AI research agents generate hypotheses in a precise, machine-testable format, so no human hours are spent translating vague intuition into testable form. The result is a system where an idea can die within hours, at negligible cost.
Kill Criteria Before the Test
Every test at Bountify begins with its ending written down. Before a hypothesis enters validation, we fix the thresholds it must clear and the exact conditions under which it dies. Deciding after the results arrive invites motivated reasoning: parameters get adjusted, evaluation windows get shifted, and a corpse gets dressed up as a survivor. Pre-registered kill criteria make the process, rather than the researcher’s hopes, the final judge of what continues and what does not.
We apply the same falsification standard to the research process itself. When retired strategies decay faster than our models predicted, or when paper trading diverges materially from backtested expectations, the discrepancy is treated as evidence about the pipeline, not merely about one idea. A validation process that never fails its own audits is not a strong process; it is an unexamined one, and unexamined processes eventually manufacture false discoveries at industrial scale.
Most trading ideas deserve to die, and the health of a quantitative research organization is measured by how efficiently it obliges them. Our advantage is not that we generate better ideas than everyone else; the market humbles that ambition quickly. Our advantage is that we execute the bad ideas faster, cheaper, and more honestly, so that capital, computation, and human attention remain concentrated on the few hypotheses that repeatedly refuse to die.